Platinum-based antitumor drugs containing enantiomerically pure α-trifluoromethyl alanine as ligand

Journal of Medicinal Chemistry

Volumn 48, Issue 24, 2005, Pages 7821-7828

  Margiotta, Nicola ^a   Papadia, Paride ^b   Lazzaro, Francesco ^c   Crucianelli, Marcello ^c   De Angelis, Francesco ^c   Pisano, Claudio ^d   Vesci, Loredana ^d   Natile, Giovanni ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF SALENTO   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d Research and Development Oncology Area   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINO ACID; ALPHA TRIFLUOROMETHYLALANINE; AMINO ACID; ANTINEOPLASTIC AGENT; CISPLATIN; LIGAND; PLATINUM COMPLEX; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; CELL CYCLE G2 PHASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MITOSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; TUMOR CELL LINE;

ALANINE; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; G2 PHASE; HUMANS; LIGANDS; ORGANOPLATINUM COMPOUNDS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 28244441989     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0504003     Document Type: Article

References (45)

1. Iakovidis A.; Hadjiliadis N. Complex compounds of platinum (II) and (IV) with amino acids, peptides and their derivatives. Coord. Chem. Rev. 1994, 135/136, 17-63.
2. Appleton, T. G. Donor atom preferences in complexes of platinum and palladium with amino acids and related molecules. Coord. Chem. Rev. 1997, 166, 313-359.
3. Lippert, B., Ed. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug; Wiley-VCH: Weinheim, Germany, 1999; 563 pp.
4. Bersanetti, E.; Pasini, A.; Pezzoni, G.; Pratesi, G.; Savi, G.; Supino R.; Zunino, F. Antitumor complexes of platinum with carrier molecules. 2. Mixed complexes of amino acids and tert-butylamine. Inorg. Chim. Acta 1984, 93, 167-172.
5. Colombo, A.; Di Gioia, R.; Pasini, A.; Dasdia, T.; Zunino, F. Antitumor complexes of platinum with carrier molecules. 3. Cytotoxicity of some platinum amino acid complexes against cisplatin-sensitive and resistant L1210 leukemia cells. Inorg. Chim. Acta 1986, 125, L1-L3.
6. Jin, V. X.; Ranford, J. D. Complexes of platinum(II) or palladium-(II) with 1,10-phenanthroline and amino acids. Inorg. Chim. Acta 2000, 304, 38-44.
7. Sandman, K. E.; Fuhrmann, P.; Lippard, S. J. A mechanism-based, solution-phase method for screening combinatorial mixtures of potential platinum anticancer drugs. J. Biol. Inorg. Chem. 1998, 3, 74-80 and references therein.
8. 2O./m>rg. Chim. Acta 1990, 175, 57-63.
9. Beck, W. Synthesis and reactivity of platinum and palladium complexes with α-amino acids, peptides, and derivatives thereof: platinum(II) as amino protecting group. Pure Appl. Chem. 1988, 60, 1357-1362.
10. Pavone, V.; Lombardi, A.; Di Blasio, B.; Benedetti, E.; Pedone, C. Platinum(II) complexes of amino acids and peptides. I. Structural analysis of trans-bis(L-alanine)dichloroplatinum. Inorg. Chim. Acta 1988, 153, 171-174.
11. Appleton, T. G.; Hall, J. R. Platinum(II) complexes with glycine as an oxygen-bound unidenate ligand. J. Chem. Soc., Chem. Commun. 1983, 911-913.
12. Appleton, T. G.; Hall, J. R.; Ralph, S. F. Reactions of platinum(II) aqua complexes. 3. Multinuclear (nitrogen-15, platinum-195, carbon-13, and proton) NMR study of reactions of aqua and hydroxo complexes with glycine and (methylimino)diacetic acid. Inorg. Chem. 1985, 24, 673-677.
13. - (n = 1, 2, 3), with platinum(II) ammine complexes. Aust. J. Chem. 1986, 39, 1347-1362.
14. Gibson, D.; Rosenfeld, A.; Apfelbaum, H.; Blum, J. Multinuclear (platinum-195, nitrogen-15, carbon-13) NMR studies of the reactions between cis-diaminediaquaplatinum(II) complexes and aminomalonate. Inorg. Chem. 1990, 29, 5125-5129.
15. Odenheimer, B.; Wolf, W. Reactions of cisplatin with sulfur-containing amino acids and peptides. I. Cysteine and glutathione. Inorg. Chim. Acta 1982, 66, L41-L43.
16. Borch, R. F.; Markman, M. Biochemical modulation of cisplatin toxicity. Pharmacol. Ther. 1989, 41, 371-380.
17. Corden, B. J. Reaction of platinum(II) antitumor agents with sulfhydral compounds and the implications for nephrotoxicity. Inorg. Chim. Acta 1987, 137, 125-130.
18. Wallach, D. F. H. Some biochemical anomalies that can contribute to the malignant behavior of cancer cells. J. Mol. Med. 1976, 1, 97-107.
19. Williams, D. R. Metals, ligands, and cancer. Chem. Rev. 1972, 72, 203-213.
20. Fuertes, M. A.; Alonso, C.; Pérez, J. M. Biochemical modulation of cisplatin mechanisms of action: Enhancement of antitumor activity and circumvention of drug resistance. Chem. Rev. 2003, 103, 645-662.
21. Wong, E.; Giandomenico, C. M. Current status of platinum-based antitumor drugs. Chem. Rev. 1999, 99, 2451-2466.
22. 2O. Inorg. Chim. Acta 1980, 46, L32.
23. Charlson, A. J.; Shorland, W. A. The antitumor activity of some platinum(II) complexes of amino acids. Inorg. Chim. Acta 1984, 93, L67-L68.
24. Asensio, A.; Bravo, P.; Crucianelli, M.; Farina, A.; Fustero, S.; García Soler, J.; Meille, S. V.; Panzeri, W.; Viani, F.; Volonterio, A.; Zanda, M. Synthesis of non-racemic α-trifluoromethyl α-amino acids from sulfinimines of trifluoropyruvate. Eur. J. Org. Chem. 2001, 1449-1458.
25. Bravo, P.; Crucianelli, M.; Vergani, B.; Zanda, M. Sulfinimines of trifluoropyruvate: Novel intermediates for chiral non racemic α-trifluoromethyl α-amino acids. Tetrahedron Lett. 1998, 39, 7771-7774.
26. Qiu, X.-L.; Meng, W.-D.; Qing, F.-L. Synthesis of fluorinated amino acids. Tetrahedron 2004, 60, 6711-6745.
27. Koksch, B.; Sewald, N.; Jakubke, H. D. Synthesis and Incorporation of α-Trifluoromethyl-Substituted Amino Acids into Peptides. In Biomedical Frontiers of Fluorine Chemistry; Ojima, I., McCarthy, J. R., Welch, J. T., Eds.; ACS Symposium Series 639; American Chemical Society: Washington, DC, 1996; Chapter 3, pp 42-58.
28. Bravo, P.; Bruchè, L.; Pesenti, C.; Viani, F.; Volonterio, A.; Zanda, M.; Solution and solid-phase synthesis of trifluoromethyl peptides and mimetics. J. Fluorine Chem. 2001, 112, 153-162.
29. Lohof, E.; Planker, E.; Mang, C.; Burkhart, F.; Dechantsreiter, M. A.; Haubner, R.; Wester, H. J.; Schwaiger, M.; Holzemann, G.; Goodman, S. L.; Kessler, H. Carbohydrate derivatives for use in drug design: cyclic av-selective RGD peptides. Angew. Chem., Int. Ed. 2000, 39, 2761-2764.
30. Zanda, M. Trifluoromethyl group: an effective xenobiotic function for peptide backbone modification. New J. Chem. 2004, 28, 1401-1411.
31. Lazzaro, F.; Crucianelli, M.; De Angelis, F.; Frigerio, M.; Malpezzi, L.; Volonterio, A.; Zanda, M. Stereoselective synthesis of (R)- and (S)-α-Tfm aspartic acid via titanium enolate addition to a sulfmimine of trifluoropyruvate. Tetrahedron: Asymmetry 2004, 15, 889-893.
32. Bravo, P.; Capelli, S.; Valdo Meille, S.; Viani, F.; Zanda, M. Synthesis of optically pure (R) and (S)-α-Trifluoromethyl alanine. Tetrahedron: Asymmetry 1994, 5, 2009-2018.
33. Koch, D.; Beck, W. Metallkomplexe mit biologisch wichtigen Liganden, CXL. Halbsandwich-komplexe von ruthenium(II), rhodium(III), iridium(III) sowie palladium(II)- und platin(II)-komplexe mit N,O-chelaten von fluor- und thiophen-haltigen α-aminosäuren (Metal complexes with biological ligands. Complexes of ruthenium(II), rhodium(III), iridium(III) with palladium(II) and platin(II) with N,O-chelation of fluoro and thiophen amino acids). Z. Naturforsch. 2001, 56b, 1271-1280.
34. Berners-Price, S. J.; Sadler, P. J. Coordination chemistry of metallodrugs: insights into biological speciation from NMR spectroscopy. Coord. Chem. Rev. 1996, 151, 1-40.
35. 2(2,9-dimethyl-1,10- phenanthroline)]. Z. Kristallogr. 2002, 217, 492-496.
36. 2-phen)]. Inorg. Chim. Acta 1995, 235, 205-213.
37. 2(dmphen)]. J. Chem. Soc., Dalton Trans. 1991, 1007-1015.
38. Kato, M.; Takahashi, J. Anion-controlled π-stacks of (ethylene-diamine-N,N′)(1,10-phenanthroline-N,N′)platinum(II). Acta Crystallogr. 1999, C55, 1809-1812.
39. Schlosser, M. Parametrization of substituents: Effects of fluorine and other heteroatoms on OH, NH, and CH acidities. Angew. Chem., Int. Ed. 1998, 110, 1496-1513.
40. It is worth noting that in passing from the natural amino acid to the trifluoromethyl analogue, the absolute configuration is preserved.
41. 2 (L = monofunctional thiourea derivative; L-L = bifunctional thiourea derivative). Inorg. Chem. 1998, 37, 708-716.
42. Pasini, A.; Caldirola, C.; Spinelli, S.; Valsecchi, M. Comments on different synthetic methods for the preparation of diammine and bis(amine) organodicarboxylatoplatinum(II) complexes. Inorg. Met.-Org. Chem. 1993, 23, 1021-1060.
43. Margiotta, N.; Papadia, P.; Fanizzi, F. P.; Natile, G. Mono- and bis-guanosine adducts of platinum complexes with carrier ligands having in-plane steric bulk: The case of 1,10-phenanthroline and 2,9-dimethyl-1,10- phenanthroline. Eur. J. Inorg. Chem. 2003, 1136-1144.
44. Feltham, R. D.; Hayter, R. G. The electrolyte type of ionized complexes. J. Chem. Soc. 1964, 4587-4591.
45. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112.